KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC Meeting Abstract
| Authors: | Wakelee, H. A.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; He, J.; Gao, S.; Chen, K. N.; Dooms, C. A.; Majem, M.; Eigendorff, E.; Martinengo, G. L.; Bylicki, O.; Rodriguez-Abreu, D.; Chaft, J. E.; Novello, S.; Yang, J.; Keller, S. M.; Samkari, A.; Spicer, J. |
| Abstract Title: | KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-10 |
| Language: | English |
| ACCESSION: | WOS:001043181100006 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2023.41.17_suppl.LBA100 |
| Notes: | Meeting Abstract: LBA100 -- Meeting was also available virtually -- Source: Wos |
